Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Ranbaxy's empty promises
CNN Money
Monday, February 3, 2014 - 8:33am
tags:
Ranbaxy, drug manufacturing, India
Lupin's net profit beats forecast on generic launches
Yahoo/Reuters
Monday, February 3, 2014 - 8:32am
tags:
earnings, generics, Lupin
AstraZeneca Vs. NTDs: Does Profitability Win Out?
Seeking Alpha
Monday, February 3, 2014 - 8:31am
tags:
AstraZeneca, India, R&D
Cosmo Scraps Partnership Plans After Santarus Windfall, CEO Says
Bloomberg
Monday, February 3, 2014 - 8:29am
tags:
Santarus, Cosmo Pharma, Rifamycin SV MMX
Pfizer Focuses on Experimental Drugs to Regain Revenue Losses
Wall St Cheat Sheet
Monday, February 3, 2014 - 8:25am
tags:
Pfizer, Prevnar, palbociclib
Biotech Boomlet Set To Smash IPO Record For Two-Week Period
Seeking Alpha
Monday, February 3, 2014 - 8:22am
tags:
biotech, IPOs, Dicerna, Celladon
Novartis to cut or transfer up to 4,000 pharma jobs - paper
Yahoo/Reuters
Monday, February 3, 2014 - 8:20am
tags:
Novartis, layoffs
GSK to launch late-stage clinical trials on 10 new drugs -paper
Yahoo/Reuters
Monday, February 3, 2014 - 8:17am
tags:
GSK, clinical trials
FDI in pharma (in India) jumps to $1.25 billion during April -November period
Economic Times, India
Sunday, February 2, 2014 - 11:45am
tags:
India
Forest Laboratories, Inc.: Feelings of Deja Vu?
Motley Fool
Sunday, February 2, 2014 - 11:37am
tags:
Namenda, Forest Labs, patent cliff, patents, generics
Fierce Competition in the Diabetes Drug Market
Motley Fool
Sunday, February 2, 2014 - 11:36am
tags:
diabetes, GSK, Sanofi, Astra Zeneca, Bristol-Myers Squibb, Novo Nordisk, Eli Lily, Takeda
3 Things to Watch in Merck's Upcoming Earnings
Motley Fool
Sunday, February 2, 2014 - 11:34am
tags:
Merck, earnings
The Case For Questcor
Seeking Alpha
Sunday, February 2, 2014 - 11:32am
tags:
Questcor Pharmaceuticals
Inovio Neglected The Sign: Don't Feed The Bears!
Seeking Alpha
Sunday, February 2, 2014 - 11:31am
tags:
Inovio
This Week in Biotech: Let's Get Clinical!
Motley Fool
Sunday, February 2, 2014 - 11:30am
tags:
AbbVie, Enanta Pharmaceuticals, ABT-450, hepatitis C, Medivation, Xtandi, prostate cancer, Astellas, Geron, imetelstat, PSMA-ADC, Progenics Pharmaceuticals, Idenix
A Unique Take On Pharmaceutical Research
Bioresearch Online
Saturday, February 1, 2014 - 11:14am
tags:
UCB Pharmaceuticals
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
FierceBiotech
Saturday, February 1, 2014 - 11:12am
tags:
PG324, ocular hypertension, glaucoma, Aerie Pharma
Johnson & Johnson's 3 Fastest-Growing Businesses
Motley Fool
Saturday, February 1, 2014 - 11:09am
tags:
JNJ
Heart Attack Risk of Testosterone Drugs Under U.S. Review
Bloomberg
Saturday, February 1, 2014 - 10:54am
tags:
testosterone
Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation
Seeking Alpha
Saturday, February 1, 2014 - 10:53am
tags:
Galena Biopharma

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.